Treatment of:

• Inflammatory and degenerative forms of rheumatism: rheumatoid arthritis, ankylosing spondylitis, osteoarthritis and spondylarthritis, painful syndromes of the vertebral column, non-articular rheumatism.
• Post-traumatic and post-operative pain, inflammation, and swelling, e.g. following dental or orthopaedic surgery.
• Painful and/or inflammatory conditions in gynaecology, e.g. primary dysmenorrhoea or adnexitis.

As a general recommendation, the dose should be individually adjusted. Adverse effects may be minimized by using the lowest effective dose for the shortest duration necessary to control symptoms
General target population: adults
The recommended initial daily dose is 100 to 150 mg, administered as 1 tablet of Voveran prolongedreleased 100 mg or as 2 tablets of Voveran prolonged-released 75 mg.

In milder cases, as well as for long-term therapy, 75 to 100 mg daily is usually sufficient.
Where the symptoms are most pronounced during the night or in the morning, Voveran prolongedrelease 75 mg and 100 mg should preferably be taken in the evening.

1. Known hypersensitivity to the active substance or to any of the excipients.
2. Active gastric or intestinal ulcer, bleeding or perforation (see sections WARNINGS AND PRECAUTIONS and ADVERSE DRUG REACTIONS).
3. Last trimester of pregnancy (see section WOMEN OF CHILD-BEARING POTENTIAL, PREGNANCY, BREAST-FEEDING AND FERTILITY).
4. Hepatic failure.
5. Renal failure (GFR <15 mL/min/1.73m2).
6. Severe cardiac failure (see section WARNINGS AND PRECAUTIONS).
7. Like other non-steroidal anti-inflammatory drugs (NSAIDs), Voveran is also contraindicated in patients in whom attacks of asthma, urticaria, or acute rhinitis are precipitated by acetylsalicylic acid or other NSAIDs.